Shilpa Medicare Limited (SHILPAMED.BO)
INR 825.9
(-0.56%)
INR 825.9
(-0.56%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 3.54 Billion INR | -43.4% |
| 2022 | 6.26 Billion INR | -17.11% |
| 2021 | 7.55 Billion INR | 20.11% |
| 2020 | 6.29 Billion INR | 1.33% |
| 2019 | 6.21 Billion INR | 43.8% |
| 2018 | 4.31 Billion INR | 9.89% |
| 2017 | 3.93 Billion INR | 9.74% |
| 2016 | 3.58 Billion INR | 33.82% |
| 2015 | 2.67 Billion INR | 3.58% |
| 2014 | 2.58 Billion INR | 10.58% |
| 2013 | 2.33 Billion INR | 49.38% |
| 2012 | 1.56 Billion INR | 16.56% |
| 2011 | 1.34 Billion INR | 6.32% |
| 2010 | 1.26 Billion INR | 8.32% |
| 2009 | 1.16 Billion INR | 78.52% |
| 2008 | 652.74 Million INR | 149.06% |
| 2007 | 262.07 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 1 Billion INR | -1.06% |
| 2023 Q1 | 1.72 Billion INR | 3.48% |
| 2023 Q3 | 1.89 Billion INR | 1.48% |
| 2023 FY | 3.54 Billion INR | -43.4% |
| 2023 Q4 | 1.01 Billion INR | -46.55% |
| 2023 Q2 | 1.87 Billion INR | 8.64% |
| 2022 Q2 | 1.46 Billion INR | -6.83% |
| 2022 Q4 | 1.66 Billion INR | 6.07% |
| 2022 FY | 6.26 Billion INR | -17.11% |
| 2022 Q1 | 1.57 Billion INR | -28.77% |
| 2022 Q3 | 1.56 Billion INR | 7.18% |
| 2021 FY | 7.55 Billion INR | 20.11% |
| 2021 Q2 | 1.93 Billion INR | 19.58% |
| 2021 Q1 | 1.61 Billion INR | -3.77% |
| 2021 Q3 | 1.8 Billion INR | -6.28% |
| 2021 Q4 | 2.2 Billion INR | 22.01% |
| 2020 Q3 | 1.27 Billion INR | -27.13% |
| 2020 FY | 6.29 Billion INR | 1.33% |
| 2020 Q1 | 1.58 Billion INR | 2693.11% |
| 2020 Q2 | 1.75 Billion INR | 10.47% |
| 2020 Q4 | 1.67 Billion INR | 31.31% |
| 2019 Q4 | 56.8 Million INR | -96.72% |
| 2019 Q2 | 1.97 Billion INR | 84.47% |
| 2019 FY | 6.21 Billion INR | 43.8% |
| 2019 Q1 | 1.07 Billion INR | 15.46% |
| 2019 Q3 | 1.73 Billion INR | -12.46% |
| 2018 Q2 | 1.17 Billion INR | -8.26% |
| 2018 FY | 4.31 Billion INR | 9.89% |
| 2018 Q3 | 1.07 Billion INR | -8.36% |
| 2018 Q1 | 1.27 Billion INR | 0.35% |
| 2018 Q4 | 928.37 Million INR | -13.49% |
| 2017 FY | 3.93 Billion INR | 9.74% |
| 2017 Q3 | 941.67 Million INR | -21.23% |
| 2017 Q2 | 1.19 Billion INR | 30.44% |
| 2017 Q1 | 916.49 Million INR | -29.25% |
| 2017 Q4 | 1.27 Billion INR | 35.08% |
| 2016 Q1 | 809.38 Million INR | -22.05% |
| 2016 FY | 3.58 Billion INR | 33.82% |
| 2016 Q4 | 1.29 Billion INR | 35.92% |
| 2016 Q3 | 953.07 Million INR | -6.23% |
| 2016 Q2 | 1.01 Billion INR | 25.58% |
| 2015 Q4 | 1.03 Billion INR | 16.49% |
| 2015 FY | 2.67 Billion INR | 3.58% |
| 2015 Q1 | 684.75 Million INR | 22.09% |
| 2015 Q2 | 858.53 Million INR | 25.38% |
| 2015 Q3 | 891.35 Million INR | 3.82% |
| 2014 Q2 | 659.85 Million INR | 3.94% |
| 2014 FY | 2.58 Billion INR | 10.58% |
| 2014 Q4 | 560.86 Million INR | -23.01% |
| 2014 Q3 | 728.47 Million INR | 10.4% |
| 2014 Q1 | 634.83 Million INR | 39.31% |
| 2013 Q2 | 622.45 Million INR | 11.61% |
| 2013 FY | 2.33 Billion INR | 49.38% |
| 2013 Q4 | 455.68 Million INR | -34.99% |
| 2013 Q3 | 700.95 Million INR | 12.61% |
| 2013 Q1 | 557.71 Million INR | 38.22% |
| 2012 FY | 1.56 Billion INR | 16.56% |
| 2012 Q2 | 361.3 Million INR | -9.46% |
| 2012 Q3 | 400.5 Million INR | 10.85% |
| 2012 Q1 | 399.03 Million INR | 0.34% |
| 2012 Q4 | 403.49 Million INR | 0.74% |
| 2011 FY | 1.34 Billion INR | 6.32% |
| 2011 Q1 | 306.8 Million INR | 0.0% |
| 2011 Q4 | 397.69 Million INR | 21.43% |
| 2011 Q3 | 327.51 Million INR | 5.64% |
| 2011 Q2 | 310.03 Million INR | 1.05% |
| 2010 FY | 1.26 Billion INR | 8.32% |
| 2009 FY | 1.16 Billion INR | 78.52% |
| 2008 FY | 652.74 Million INR | 149.06% |
| 2007 FY | 262.07 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Ajanta Pharma Limited | 21.06 Billion INR | 83.162% |
| Amrutanjan Health Care Limited | 1.55 Billion INR | -127.869% |
| Sigachi Industries Limited | 2 Billion INR | -77.141% |
| Bal Pharma Limited | 770.19 Million INR | -360.515% |
| Ind-Swift Laboratories Limited | 6.19 Billion INR | 42.74% |
| Medico Remedies Limited | 262.14 Million INR | -1253.02% |
| Lasa Supergenerics Limited | 121.02 Million INR | -2830.564% |
| Venus Remedies Limited | 2.18 Billion INR | -62.507% |
| Sun Pharma Advanced Research Company Limited | -602.4 Million INR | 688.782% |
| Alpa Laboratories Limited | 188.89 Million INR | -1777.689% |
| Nectar Lifesciences Limited | 2.97 Billion INR | -19.34% |
| Aarti Drugs Limited | 8.31 Billion INR | 57.35% |
| Lupin Limited | 123.71 Billion INR | 97.133% |
| Aurobindo Pharma Limited | 154.68 Billion INR | 97.707% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 97.167% |
| Windlas Biotech Limited | 1.33 Billion INR | -164.928% |
| Suven Life Sciences Limited | -200.79 Million INR | 1866.391% |
| Eris Lifesciences Limited | 10.42 Billion INR | 65.983% |
| Valiant Laboratories Limited | -60.66 Million INR | 5946.731% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | 84.375% |
| Solara Active Pharma Sciences Limited | 861.2 Million INR | -311.851% |
| Ipca Laboratories Limited | 29.8 Billion INR | 88.102% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | 4.02% |
| Achyut Healthcare Limited | 4.86 Million INR | -72865.666% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 98.628% |
| Bajaj HealthCare Limited | 1.47 Billion INR | -140.987% |
| RPG Life Sciences Limited | 2.48 Billion INR | -42.846% |
| Mankind Pharma Limited | 44.52 Billion INR | 92.033% |
| Laurus Labs Limited | 24.62 Billion INR | 85.594% |
| Piramal Pharma Limited | 24.47 Billion INR | 85.506% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -276.365% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 92.414% |
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 86.756% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 94.885% |
| Unichem Laboratories Limited | 4.86 Billion INR | 27.093% |
| Sequent Scientific Limited | 2.97 Billion INR | -19.073% |
| Novartis India Limited | 1.32 Billion INR | -167.304% |
| Wanbury Limited | 1.73 Billion INR | -104.945% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | 13.979% |
| Wockhardt Limited | 16.24 Billion INR | 78.16% |
| Themis Medicare Limited | 1.5 Billion INR | -135.844% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -443.505% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 81.943% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 71.472% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 97.832% |
| Divi's Laboratories Limited | 32.44 Billion INR | 89.066% |
| NATCO Pharma Limited | 25.73 Billion INR | 86.218% |
| Gufic Biosciences Limited | 4.16 Billion INR | 14.897% |
| IOL Chemicals and Pharmaceuticals Limited | 4.58 Billion INR | 22.571% |
| Ind-Swift Limited | 2.17 Billion INR | -63.259% |
| Procter & Gamble Health Limited | 5.78 Billion INR | 38.65% |
| FDC Limited | 8.33 Billion INR | 57.445% |
| Krebs Biochemicals & Industries Limited | 192.72 Million INR | -1740.355% |
| Granules India Limited | 16.79 Billion INR | 78.887% |
| Medicamen Biotech Limited | 495.49 Million INR | -615.822% |
| Alkem Laboratories Limited | 52.29 Billion INR | 93.218% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 43.001% |
| Biofil Chemicals and Pharmaceuticals Limited | 14.57 Million INR | -24227.394% |
| Brooks Laboratories Limited | 65.62 Million INR | -5305.152% |
| Megasoft Limited | 342.07 Million INR | -936.879% |
| ZIM Laboratories Limited | 1.26 Billion INR | -179.967% |
| Strides Pharma Science Limited | 14.38 Billion INR | 75.349% |
| Neuland Laboratories Limited | 8.24 Billion INR | 56.996% |
| Morepen Laboratories Limited | 6.16 Billion INR | 42.433% |
| Hikal Limited | 3.14 Billion INR | -12.847% |
| Indoco Remedies Limited | 6.04 Billion INR | 41.29% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 39.176% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -471.635% |
| Mangalam Drugs & Organics Limited | 703.6 Million INR | -404.098% |
| Hester Biosciences Limited | 1.27 Billion INR | -178.48% |